数据显示，永赢基金旗下1只基金位居乐心医疗十大流通股东。医疗器械ETF（159883）三季度新进十 大流通股东，持有股数93.62万股，占流通股的比例为0.58%。根据测算，今日浮盈赚取约73.96万元。 连续3天上涨期间浮盈赚取132.94万元。 医疗器械ETF（159883）成立日期2021年4月22日，最新规模47.3亿。今年以来收益11.54%，同类排名 820/5517；近一年收益20.4%，同类排名3517/4203；成立以来亏损45.58%。 医疗器械ETF（159883）基金经理为储可凡。 1月13日，乐心医疗涨5.15%，截至发稿，报16.14元/股，成交2.48亿元，换手率9.79%，总市值35.28亿 元。乐心医疗股价已经连续3天上涨，区间累计涨幅10.19%。 资料显示，广东乐心医疗电子股份有限公司位于广东省中山市火炬开发区东利路105号A区，成立日期 2002年7月18日，上市日期2016年11月16日，公司主营业务涉及家庭健康管理事业,专业从事家用医疗健 康电子产品的研发、生产和销售,及乐心智能健康云平台的研发与运营。主营业务收入构成为：家用医 疗产品66.29%，家用健康产品24 ...

1月12日，乐心医疗涨5.09%，截至发稿，报15.27元/股，成交1.03亿元，换手率4.23%，总市值33.38亿 元。 资料显示，广东乐心医疗电子股份有限公司位于广东省中山市火炬开发区东利路105号A区，成立日期 2002年7月18日，上市日期2016年11月16日，公司主营业务涉及家庭健康管理事业,专业从事家用医疗健 康电子产品的研发、生产和销售,及乐心智能健康云平台的研发与运营。主营业务收入构成为：家用医 疗产品66.29%，家用健康产品24.17%，其他7.55%，智能可穿戴1.99%。 截至发稿，储可凡累计任职时间2年153天，现任基金资产总规模62.82亿元，任职期间最佳基金回报 103.17%， 任职期间最差基金回报-30.27%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，永赢基金旗下1只基金位居乐心医疗十大流通股东。医疗器械ETF（159883）三季度新进十 大流通股东，持有股数93.62万股，占流通股的比例为0. ...

港股医疗ETF（159366）紧密跟踪中证港股通医疗主题指数，1月5日午后，中证港股通医疗主题指数 （932069）强势上涨3.57%，成分股微创脑科学上涨23.19%，脑动极光-B上涨18.24%，昭衍新药港股涨 超13%，映恩生物-B，医脉通等个股跟涨。港股医疗ETF（159366）上涨5.34%。中证港股通医疗主题 指数从港股通范围内选取50只业务涉及医疗器械、医疗商业与服务、制药与生物科技服务等领域的上市 公司证券作为指数样本，全面覆盖港股医疗板块龙头，能够较为充分地分享港股医疗龙头企业的成长红 利。 （文章来源：21世纪经济报道） 国开证券指出，脑机接口、AI应用等医疗"硬科技"领域也是关注方向。脑机接口作为人工智能领域的前 沿技术，在政策的支持下，有望在医疗精神神经类疾病、康复及健康管理等领域加速拓展运用。同时， 2025年来国内外人工智能技术、产品及商业化运用均快速发展，医药行业作为其最重要的应用领域之 一，AI+医药/医疗的发展将大有可为，有望在药物研发、辅助诊断、服务等应用领域展现较大的发展潜 力，建议继续关注。 医疗器械ETF（159883）跟踪专注医疗器械细分板块的中证医疗器械指数，规模 ...

Group 1 - Core viewpoint: Berry Genomics has seen a stock price increase of 1.25%, reaching 11.30 CNY per share, with a total market capitalization of 3.995 billion CNY as of the report date [1] - Company overview: Berry Genomics, established on April 14, 1997, specializes in gene testing and sales of related equipment and reagents, with its main revenue sources being reagent sales (45.74%), medical testing services (31.24%), basic research services (18.33%), equipment sales (3.48%), and others (1.20%) [1] Group 2 - Major shareholders: The top circulating shareholder of Berry Genomics includes a fund from Yongying Fund, with the Medical Device ETF (159883) newly entering the top ten shareholders in Q3, holding 1.5268 million shares, which is 0.46% of the circulating shares [2] - ETF performance: The Medical Device ETF (159883) has a total size of 4.73 billion CNY, with a year-to-date return of 1.32%, ranking 3982 out of 4189 in its category, and a one-year loss of 0.34%, ranking 4000 out of 4188 [2]

Group 1 - The core viewpoint of the news is that Dian Diagnostics has seen a stock price increase of 5.09%, reaching 15.91 yuan per share, with a trading volume of 1.67 billion yuan and a market capitalization of 99.43 billion yuan as of the report date [1] - Dian Diagnostics, established on September 5, 2001, and listed on July 19, 2011, provides medical diagnostic services primarily to various healthcare institutions, with its main business revenue composition being 65.34% from channel products and 34.66% from diagnostic services [1] Group 2 - Among the top circulating shareholders of Dian Diagnostics, a fund under Yongying Fund ranks first, while the Medical Device ETF (159883) entered the top shareholders in the third quarter, holding 3.0875 million shares, which is 0.62% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 4.73 billion yuan, showing a year-to-date return of 1.98% and a one-year loss of 1.18% [2]

Group 1 - The core point of the news is that Jianerkang's stock price has increased for six consecutive days, with a total increase of 7.34% during this period, reaching a price of 28.66 yuan per share and a market capitalization of 4.471 billion yuan [1] - Jianerkang Medical Technology Co., Ltd. specializes in the research, production, and sales of disposable medical devices and disinfectant hygiene products, with its main business revenue composition being: nursing products 33.19%, surgical consumables 30.64%, polymer and auxiliary products 18.46%, disinfecting and cleaning products 16.93%, and others 0.79% [1] - The company is located in Jiangsu Province, China, and was established on June 6, 2000, with its listing date set for November 7, 2024 [1] Group 2 - Among Jianerkang's top ten circulating shareholders, a fund under Yongying Fund ranks first, and the Medical Device ETF (159883) entered the top ten circulating shareholders in the third quarter, holding 285,100 shares, which is 0.73% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a latest scale of 4.73 billion yuan, and has recorded a year-to-date return of 4.89% [2] - The fund manager of the Medical Device ETF is Shu Kefa, who has been in the position for 2 years and 111 days, with the fund's total asset scale at 6.282 billion yuan [3]

Group 1 - The core viewpoint of the news is the performance and market position of Zhonghong Medical, which saw a stock price increase of 5.78% to 14.46 CNY per share, with a total market capitalization of 6.201 billion CNY [1] - Zhonghong Medical specializes in the research, production, and sales of high-quality disposable protective gloves, with its main business revenue composition being 89.48% from health protection products, 6.22% from safety injection products, and 4.30% from innovative incubation products [1] - The company is located in the Luan Nan Economic Development Zone in Tangshan, Hebei Province, and was established on December 22, 2010, with its listing date on April 27, 2021 [1] Group 2 - From the perspective of major circulating shareholders, Yongying Fund has a fund that ranks among the top shareholders of Zhonghong Medical, while the Medical Device ETF (159883) entered the top ten circulating shareholders in the third quarter, holding 794,700 shares, which is 0.2% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a latest scale of 4.73 billion CNY, and has recorded a year-to-date return of 7.36% [2] - The fund manager of the Medical Device ETF is Shu Kefa, who has a total fund asset scale of 6.282 billion CNY, with the best fund return during his tenure being 103.17% and the worst being -30.27% [3]

Group 1 - Lidman shares increased by 5.5% on November 17, reaching 9.59 CNY per share, with a trading volume of 263 million CNY and a turnover rate of 5.36%, resulting in a total market capitalization of 5.217 billion CNY [1] - The stock price of Lidman has risen for six consecutive days, with a cumulative increase of 18.98% during this period [1] - Lidman, established on November 5, 1997, and listed on February 16, 2012, specializes in in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials, with the revenue composition being 67.84% from in vitro diagnostic reagents, 14.17% from diagnostic instruments, 13.21% from other sources (such as property leasing/management), and 4.78% from biochemical raw materials [1] Group 2 - Among Lidman's top ten circulating shareholders, a fund under Yongying Fund is included, and the Medical Device ETF (159883) entered the top ten shareholders in the third quarter, holding 2.0113 million shares, which is 0.37% of the circulating shares [2] - The Medical Device ETF (159883) has generated a floating profit of approximately 1.0056 million CNY today and a total floating profit of 2.9164 million CNY during the six-day increase [2] - The Medical Device ETF was established on April 22, 2021, with a current scale of 4.73 billion CNY, yielding 9.67% year-to-date, ranking 3702 out of 4216 in its category, and 1.7% over the past year, ranking 3689 out of 3956, while it has incurred a loss of 46.82% since inception [2] Group 3 - The fund manager of the Medical Device ETF (159883) is Shu Kefa, who has been in the position for 2 years and 97 days, managing a total fund size of 6.282 billion CNY [3] - During Shu Kefa's tenure, the best fund return was 103.17%, while the worst return was -30.27% [3]

Group 1 - The core point of the news is that Innotech's stock price increased by 5.16%, reaching 35.89 CNY per share, with a total market capitalization of 4.916 billion CNY [1] - Innotech specializes in the research, production, and sales of POCT rapid diagnostic products, with a revenue composition of 96.49% from respiratory series, 2.99% from other reagents, and 0.51% from prenatal and postnatal care series [1] Group 2 - Among Innotech's top ten circulating shareholders, a fund under Yongying Fund ranks as a significant holder, while the Medical Device ETF (159883) entered the top ten shareholders in the third quarter, holding 498,000 shares, which is 0.72% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a latest scale of 4.73 billion CNY, and has recorded a year-to-date return of 10.13% [2] - The fund manager of the Medical Device ETF is Shu Kefa, who has a total fund asset scale of 6.282 billion CNY, with the best and worst fund returns during his tenure being 103.17% and -30.27%, respectively [2]

Group 1 - Berry Genomics experienced a 5.25% increase in stock price, reaching 14.24 CNY per share, with a trading volume of 294 million CNY and a turnover rate of 6.48%, resulting in a total market capitalization of 5.034 billion CNY [1] - The company, established on April 14, 1997, specializes in high-throughput sequencing technology-based genetic testing, with revenue composition as follows: reagent sales 45.74%, medical testing services 31.24%, basic research services 18.33%, equipment sales 3.48%, and others 1.20% [1] Group 2 - The top circulating shareholder of Berry Genomics includes a fund from Yongying Fund, with the Medical Device ETF (159883) newly entering the top ten circulating shareholders in Q3, holding 1.5268 million shares, which is 0.46% of the circulating shares, resulting in an estimated floating profit of approximately 1.084 million CNY [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 4.73 billion CNY, showing a year-to-date return of 9.53% and a ranking of 3722 out of 4216 in its category, while experiencing a one-year loss of 1.36% and a ranking of 3671 out of 3937, with a cumulative loss of 46.89% since inception [2]